In conclusion, the co-modification of MSCs with SA2-PEG2000-CAR and SA2-PEG2000 represents an effective strategy to enhance MSC homing and retention within the lungs, thereby improving therapeutic outcomes for IPF. This evidence concerns the gene STAG2 and idiopathic pulmonary fibrosis.